Eversept Partners’s Standard BioTools LAB Stock Holding History

Eversept Partners’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,302,353	Closed	-$9.68M	–	64
2020 Q3	$9.68M	Buy	1,302,353 +834,430	+178%	+$5.76M	2.15%	16
2020 Q2	$1.88M	Buy	+467,923	New	+$1.63M	0.26%	50
2019 Q1	–	Sell	-50,455	Closed	-$435K	–	57
2018 Q4	$435K	Buy	+50,455	New	+$393K	0.24%	46

Other funds holding LAB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Atom Investors Austin, Texas $1.12B AUM 38.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ACM

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Eversept Partners's LAB Position: Q4 2020 in Review

Eversept Partners sold out of Standard BioTools (LAB) in Q4 2020, closing a stake of 1,302,353 shares — an estimated $9.68M sold.

Eversept Partners first reported a position in LAB in Q4 2018 and held it in 3 quarters. The position peaked at $9.68M in Q3 2020. 145 funds tracked by Wall St. Rank hold LAB as of Q4 2020.

Eversept Partners reported no remaining Standard BioTools position as of Q4 2020 after selling out during the quarter.
Eversept Partners sold 1,302,353 Standard BioTools shares in Q4 2020, an estimated $9.68M.
Eversept Partners first reported a position in Standard BioTools in Q4 2018 and held it in 3 quarters.
Eversept Partners's Standard BioTools position peaked at $9.68M in Q3 2020.
145 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2020.

Based on Eversept Partners's 13F filing for Q4 2020, filed 16 Feb 2021.